Presence of protein marks toxicity in leukemia
the ONA take:
A recent study examined the protein inositol polyphosphate 4-phosphatase II (INPP4B) in patients that had been diagnosed with acute myeloid leukemia.
When examined, the data indicated that the presence of this protein indicates a likely toxicity effect associated with chemotherapy.
Chemotherapy is a standard clinic treatment for this disease, but patients can now be screened for inositol polyphosphate 4-phosphatase II and recommended for other treatments less likely to be toxic as needed.
The researchers hope to explore exactly how the protein behaves in cancer cells, specifically related to chemoresistance, so the protein and pathway may one day be effectively targeted.
This research was led by PhD student Sewa Rijal from the Faculty of Medicine, Nursing and Health Sciences (FMNHS), under the supervision of Professor Andrew Wei and Professor Christina Mitchell, Dean of FMNHS. Findings were published in the journal Blood.
Presence of this protein indicates a likely toxicity effect associated with chemotherapy.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|